The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk

American Journal of Cardiovascular Drugs

Volumn 10, Issue 5, 2010, Pages 281-288

  Pratt, Stephen ^a   Thompson, Vincent J ^b   Elkin, Eric P ^c   Næsdal, Jørgen ^d   Srstadius, Elisabeth ^d  

^a West Coast Research   (United States)

^b Libra Clinical Research Associates   (United States)

^c ICON CLINICAL RESEARCH   (United States)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

Adverse drug reactions; Aspirin; Cardiovascular disorders; Patient compliance

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; TICLOPIDINE;

ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DYSPEPSIA; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STOMACH PAIN; TASTE DISORDER; TRANSIENT ISCHEMIC ATTACK; TREATMENT REFUSAL; UPPER GASTROINTESTINAL TRACT;

ADULT; AGED; ASPIRIN; CARDIOVASCULAR DISEASES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED;

EID: 77957298700     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11584410-000000000-00000     Document Type: Article

References (30)

1. Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005 Dec. 1;353(22):2373-83 (Pubitemid 41713749)
2. Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents: the task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004 Jan; 25(2):166-81 (Pubitemid 38112156)
3. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009 May 30;373(9678):1849-60
4. Herlitz J, Toth PP, Næsdal J. Low-dose acetylsalicylic acid therapy for CV prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs 2010;10:125-41
5. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50, 279 patients at risk for coronary artery disease. Eur Heart J 2006 Nov; 27(22):2667-74 (Pubitemid 44729867)
6. Burger W, Chemnitius JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation-review and meta-analysis. J Intern Med 2005 May; 257(5):399-414 (Pubitemid 40604544)
7. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005 Nov. 1;22(9):795-801
8. Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U. S. Preventive Services Task Force. Ann Intern Med 2002 Jan 15;136(2):161-72 (Pubitemid 34073943)
9. Taha AS, Angerson WJ, Prasad R, et al. Clinical trial: the incidence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2008 Oct. 1;28(7):878-85
10. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 Nov. 16;348(9038):1329-39
11. Glynn RJ, Buring JE, Manson JE, et al. Adherence to aspirin in the prevention of myocardial infarction. The Physicians' Health Study. Arch Intern Med 1994 Dec. 12-26;154(23):2649-57 (Pubitemid 24378434)
12. Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Annu Rev Clin Psychol 2008;4:1-32 (Pubitemid 351688514)
13. Biondi-Zoccai G, Lotrionte M. Aspirin resistance in cardiovascular disease. BMJ 2008 Jan 26;336(7637):166-7 (Pubitemid 351212649)
14. Chen WH, Cheng X, Lee PY, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007 Jul; 120(7):631-5 (Pubitemid 46977320)
15. Hanjis C, Frishman WH, Lerner RG. Aspirin resistance: mechanisms and clinical implications. Cardiol Rev 2006 Jan-Feb; 14(1):18-25 (Pubitemid 44378520)
16. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin 'resistance' and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008 Jan 26;336(7637):195-8 (Pubitemid 351212675)
17. Quittner AL, Modi AC, Lemanek KL, et al. Evidence-based assessment of adherence to medical treatments in pediatric psychology. J Pediatr Psychol 2008 Oct; 33(9):916-36; discussion 937-8
18. Lauritsen K, Degl'Innocenti A, Hendel L, et al. Symptom recording in a randomised clinical trial: paper diaries vs. electronic or telephone data capture. Control Clin Trials 2004 Dec; 25(6):585-97 (Pubitemid 39592863)
19. Taha AS, McCloskey C, Prasad R, et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009 Jul. 11;374(9684):119-25
20. Scheiman JM, Van Rensburg CJ, Uebel P, et al. Prevention of low-dose acetylsalicylic acid-associated gastric/duodenal ulcers with esomeprazole 20mg and 40 mg once daily in patients at increased risk of ulcer development: a randomized controlled trial (OBERON) [abstract]. Gastroenterology 2009;136(Suppl. 2):412
21. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008 Oct. 28;118(18):1894-909
22. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008 Sep. 16;52(12):1038-9; author reply 1039
23. Aubert RE, Epstein RS, Teagarden JR, et al. Proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel Medco outcomes study [abstract]. Circulation 2008;118(18):S815
24. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009 Mar. 31;180(7):713-8
25. Dunn SP, Macauley T, Brennan DM, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial [abstract]. Circulation 2008;118(18):S815
26. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009 Jan 22;360(4):363-75
27. Zairis M, Patsourakos N, Makrygiannis S, et al. The impact of oral proton pump inhibitors on the effectiveness of combined aspirin and clopidogrel drug therapy during the first year after elective coronary stenting [abstract]. Eur Heart J 2008;29(Suppl.): 134
28. Ramirez JF, Selzer F, Chakaprani R, et al. Proton pump inhibitor and clopidogrel combination is not associated with adverse clinical outcomes after PCI: the NHLBI dynamic registry [abstract]. J Am Coll Cardiol 2009;53(10 Suppl. 1):2903
29. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, doubleblind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008 Jan 22;51(3):256-60
30. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a protonpump inhibitor: an analysis of two randomised trials. Lancet 2009 Sep. 19;374(9694):989-97